跳至主要内容
临床试验/NCT00571610
NCT00571610已完成1 期

A Single-Center, Open-Label, Single-Arm Pilot Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Implantable Device Used to Reduce Mitral Valve Regurgitation.

Viacor2 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2006年4月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
Viacor
入组人数
5
试验地点
2
主要终点
percent of patients who remain free from device-related major adverse events (death, myocardial infarction, tamponade, emergent cardiac surgery

研究概览

简要总结

Reduction in mitral regurgitation due to safe placement of a PTMA device in the coronary sinus.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Functional MR 2+ - 4+ with left ventricular enlargement
  • Symptomatic heart failure
  • 20% - 50% LVEF

排除标准

  • mitral regurgitation of organic origins
  • recent cardiac interventions
  • severe comorbidities

结局指标

主要结局

percent of patients who remain free from device-related major adverse events (death, myocardial infarction, tamponade, emergent cardiac surgery

时间窗: 30 days

次要结局

  • percent of implanted patients who maintain a sustained 1 grade reduction in MR and reduction of mitral annulus anterior posterior dimension(30 days)
  • percent of implanted patients who exhibit improvement of clinical symptoms as one of the following: decrease in NYHA class, improvement of Minnesota QOL survey, increase exercise capacity 6 minute walk or improvement in VO2 max(30 days)

研究者

发起方
Viacor
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验